Home / Business and Economy / AbbVie vs. J&J: Growth vs. Stability Showdown
AbbVie vs. J&J: Growth vs. Stability Showdown
26 Sep
Summary
- AbbVie seeks growth in immunology and neuroscience to offset older drug losses.
- Johnson & Johnson balances innovative medicine with a robust medical technology business.
- AbbVie's FY25 revenue hit $61.2B with a 9% increase, while J&J reported $94.2B.
In the evolving healthcare industry, AbbVie and Johnson & Johnson are making distinct strategic moves. AbbVie is aggressively pursuing growth in sectors like immunology and neuroscience. This focus aims to offset the impact of expiring patents on its established blockbuster drugs. The company reported approximately $61.2 billion in revenue for FY25, a 9% increase year-over-year. Despite a net income of about $4.2 billion and a net margin near 7%, AbbVie's debt-to-equity ratio was negative 21.1x as of December 2025.
Meanwhile, Johnson & Johnson continues to thrive on diversification across its Innovative Medicine and MedTech segments. It is also strategically separating its Orthopedics business to concentrate on higher-growth medical areas. For FY25, Johnson & Johnson achieved substantial revenue of about $94.2 billion, a 6% rise from the prior year. The company posted an impressive net income of approximately $26.8 billion, resulting in a strong net margin of nearly 29%. Both companies offer substantial scale and reliable dividends to investors.
